Page 161 - 2019_07 resto del Mondo-web

BCL2 limits crizotinib efficiency in ALk+ ALCL
phoma. Am J Pathol. 2001;158(5):1889-
1890.
32. Rassidakis GZ, Sarris AH, Herling M, et al.
Differential Expression of BCL-2 Family Proteins in ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma of T/Null-Cell Lineage. Am J Pathol. 2001;159(2):527-535.
33. Fulda S, Kögel D. Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. Oncogene. 2015;34(40):5105-5113.
34. Hosokawa N, Hara T, Kaizuka T, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell. 2009;20(7):1981-1991.
35. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960-976.
36. Mönch D, Bode-Erdmann S, Kalla J, et al. A subgroup of pleural mesothelioma express- es ALK protein and may be targetable by combined rapamycin and crizotinib thera- py. Oncotarget. 2018;9(29):20781-20794.
37. Schläfli AM, Berezowska S, Adams O, Langer R, Tschan MP. Reliable LC3 and p62
autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry. Eur J Histochem. 2015;59(2):2481.
38. Holt S V., Wyspianska B, Randall KJ, James D, Foster JR, Wilkinson RW. The Development of an Immunohistochemical Method to Detect the Autophagy-Associated Protein LC3-II in Human Tumor Xenografts. Toxicol Pathol. 2011;39(3):516-523.
39. Rust R. High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma. J Clin Pathol. 2005;58(5):520- 524.
40. Desjobert C, Renalier MH, Bergalet J, et al. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood. 2011;117(24):6627- 6637.
41. Yang F, Li Q, Gong Z, et al. MicroRNA-34a Targets Bcl-2 and sensitizes human hepato- cellular carcinoma cells to sorafenib treat- ment. Technol Cancer Res Treat. 2013;13(1):77-86.
42. LiL,YuanL,LuoJ,GaoJ,GuoJ,XieX. MiR-34a inhibits proliferation and migra-
tion of breast cancer through down-regula- tion of Bcl-2 and SIRT1. Clin Exp Med. 2013;13(2):109-117.
43. Craig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, Müller A. Systemic microRNA- 34a delivery induces apoptosis and abro- gates growth of diffuse large B-cell lym- phoma in vivo. Leukemia. 2012; 26(11):2421-2424.
44. Scognamiglio I, Di Martino MT, Campani V, et al. Transferrin-conjugated SNALPs encapsulating 2’-O-methylated miR-34a for the treatment of multiple myeloma. Biomed Res Int. 2014;2014:217365.
45. Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35(2):180-188.
46. Basit F, Cristofanon S, Fulda S. Obatoclax (GX15-070) triggers necroptosis by pro- moting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ. 2013;20(9):1161-1173.
47. Sakamaki J, Ryan KM. Autophagy Determines the Path on the TRAIL to Death. Dev Cell. 2016;37(4):291-293.
haematologica | 2019; 104(7)
1439